Amgen (NASDAQ: AMGN) stock is up 13% this year but has struggled to break out above a tight trading range in recent months.

At the STAT summit, executives discuss their challenges, and hopeful signals, about breaking into markets on obesity and ...

An investor is suing Amgen Inc.'s leaders over the company’s $10.7 billion fight with the IRS, which has said the ...

The regulator has delayed its respective decision dates on whether to grant full approval to Amgen’s Lumakras in metastatic ...

Truist analyst Srikripa Devarakonda backs away from bullish call as competition mutes potential for biotech’s drug pipeline.

Amgen has a lot riding on an experimental obesity drug that it hopes will rival those of Eli Lilly and Novo Nordisk. But one ...

As for Lilly ( LLY ), Bernstein said its outperform rating “hinges on what they can do with the cash they generate from ...

Goldman Sachs analyst Salveen Richter has reiterated their bullish stance on AMGN stock, giving a Buy rating yesterday. Salveen Richter has ...

The FDA was expected to decide on the application of sotorasib and panitumumab for the treatment of metastatic colorectal ...

DBS analyst Nico Chen has maintained their bullish stance on AMGN stock, giving a Buy rating yesterday. Nico Chen has given his Buy rating due ...

Dividend stocks can be a great way to supplement your portfolio growth from share price gains and inject more cash into your ...

Amgen Inc.'s stock took a hit Monday after the biotechnology giant lost a bull, amid concerns that prices already reflect investor optimism over the obesity drug candidate, leaving more downside ...